Autolus Therapeutics (AUTL) Receives a Buy from Needham

In a report released today, Chad Messer from Needham maintained a Buy rating on Autolus Therapeutics (AUTL), with a price target of $21.00. The company’s shares closed last Friday at $7.36.

According to, Messer is a 4-star analyst with an average return of 10.1% and a 48.0% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Autolus Therapeutics with a $17.33 average price target, implying a 144.1% upside from current levels. In a report issued on May 27, Mizuho Securities also maintained a Buy rating on the stock with a $18.00 price target.

See today’s analyst top recommended stocks >>

Based on Autolus Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $269K and GAAP net loss of $33.27 million. In comparison, last year the company earned revenue of $338K and had a GAAP net loss of $29.87 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts